A case report on tenofovir induced osteoporosis

Bhavani Dhomakonda 1, *, N. MSreeja 1, Y. Vidhya Reddy 1, Ankith Reddy 1 and Tadikonda Rama Rao 2

1 Department of Pharmacy Practice, CMR College of Pharmacy, Hyderabad, Telangana, India.
2 Principal and Professor, CMR College of Pharmacy, Hyderabad, Telangana, India.
 
Research Article
International Journal of Science and Research Archive, 2024, 11(02), 183–185.
Article DOI: 10.30574/ijsra.2024.11.2.0353
Publication history: 
Received on 15 January 2024; revised on 25 February 2024; accepted on 27 February 2024
 
Abstract: 
The antiretroviral drug tenofovir, is a nucleotide analogue which is used in the treatment of HIV and hepatitis B infections. This drug works by inhibiting the HIV reverse transcriptase enzyme and prevent the synthesis of viral DNA. It is administered as a single 300 mg tablet once daily. This drug is mostly used in the combination with lamivudine, dolutegravir (TLD regimen). Although there has been success in the use of tenofovir in treating HIV infection, there have been some adverse effects associated with it. Multiple studies have implicated tenofovir associated bone loss and renal failure. In order to treat the adverse effects which are caused due to tenofovir, an alternate drug should be administered.
 
Keywords: 
Tenofovir; Reverse Transcriptase; TLD regimen; Bone loss
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0